New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 22, 2013
04:55 EDTABT, ABT, TMO, TMO, SYK, SYK, RHHBY, RHHBY, PFE, PFE, HAE, HAE, FRX, FRX, EW, EW, COV, COV, CERN, CERN, BCR, BCR, ZOLL, ZOLLSociety of Critical Care Medicine to host a conference
42nd Critical Care Congress is being held in San Juan, Puerto Rico on January 19-23.
News For ABT;BCR;CERN;COV;EW;FRX;HAE;PFE;RHHBY;SYK;TMO;ZOLL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
June 22, 2015
08:28 EDTHAEHaemonetics participates in a conference call with Benchmark
Conference call with Chief Technology Officer Dr. Jonathan White and Vice President of Global Diagnostics, Krista Thompson will be held on June 22 at 10 am hosted by Benchmark.
07:43 EDTSYKStryker management to meet with Deutsche Bank
Meeting to be held in Paris on June 22 hosted by Deutsche Bank.
07:05 EDTCERNCerner management to meet with FBR Capital
Subscribe for More Information
07:01 EDTPFEPfizer to acquire Nimenrix, Mencevax from GlaxoSmithKline for $130M
Pfizer (PFE) announced that it has entered into an agreement with GlaxoSmithKline (GSK) to acquire its quadrivalent meningitis ACWY vaccines, Nimenrix and Mencevax, for a total consideration of approximately $130M. This transaction will add two high-quality and complementary vaccines to Pfizer’s portfolio, allowing the company to reach a broader global population. Nimenrix is a single dose meningococcal ACWY-TT conjugated vaccine designed to protect against Neisseria meningitidis, an uncommon but highly contagious disease that can lead to disability and death. Mencevax is a single-dose meningococcal ACWY unconjugated polysaccharide vaccine used to control outbreaks of meningococcal infection and for travelers to countries where the disease is endemic or highly epidemic. Pfizer does not expect this transaction to have any significant impact on its 2015 financial performance. The transaction is subject to customary closing conditions as well as regulatory approvals in several markets, and is expected to occur in the second half of 2015. Pfizer’s legal advisors for the transaction were Ropes & Gray and Clifford Chance.
June 18, 2015
10:01 EDTCERNOn The Fly: Analyst Initiation Summary
Subscribe for More Information
09:35 EDTPFEActive equity options trading on open
Subscribe for More Information
06:09 EDTABTTeva raises stake in Mylan to 4.3%, Globes reports
Subscribe for More Information
June 17, 2015
19:14 EDTEWEdwards Lifesciences confirms FDA approval for SAPIEN 3 valve
Subscribe for More Information
16:20 EDTCERNCerner initiated with an Outperform at Oppenheimer
Target $89.
15:29 EDTEWFDA approves SAPIEN 3 THV artificial heart valve
Subscribe for More Information
10:00 EDTPFEOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: AbbVie (ABBV) initiated with an Overweight at Piper Jaffray... Arista Networks (ANET) initiated with a Buy at Sterne Agee CRT... Astec (ASTE) initiated with a Buy at Maxim... Bristol-Myers (BMY) initiated with an Underweight at Piper Jaffray... Community Healthcare (CHCT) initiated with an Outperform at Oppenheimer... Eli Lilly (LLY) initiated with an Overweight at Piper Jaffray... Fitbit (FIT) initiated with a Buy ahead of IPO at Dougherty... Hortonworks (HDP) initiated with a Buy at Mizuho... II-VI (IIVI) initiated with a Buy at Benchmark Co.... J Sainsbury (JSAIY) initiated with an Underperform at Credit Suisse... McDermott (MDR) initiated with an Outperform at Cowen... Merck (MRK) initiated with a Neutral at Piper Jaffray... Molina Healthcare (MOH) initiated with a Buy at UBS... Pacific DataVision (PDVW) initiated with a Buy at Canaccord... Pfizer (PFE) initiated with an Overweight at Piper Jaffray... Quest Resource (QRHC) initiated with a Buy at Roth Capital... Regional Management (RM) initiated with a Buy at Janney Capital... Rofin-Sinar (RSTI) initiated with a Buy at Benchmark Co.... Salesforce (CRM) initiated with a Neutral at Exane BNP Paribas... Sprouts Farmers Markets (SFM) initiated with a Neutral at Cleveland Research... Tesco (TSCDY) initiated with an Underperform at Credit Suisse... WM Morrison (MRWSY) initiated with a Neutral at Credit Suisse... WWE (WWE) initiated with a Buy at BTIG... World Acceptance (WRLD) initiated with a Buy at Janney Capital... Zafgen (ZFGN) initiated with a Buy at SunTrust.
08:45 EDTTMOBofA/Merrill life sciences analysts hold an analyst/industry conference call
Subscribe for More Information
07:51 EDTTMONIH draft FY16 funding budget better than expected at BofA/Merrill
Last night, the House Appropriations Labor/Health and Human Services Subcommittee released its draft FY16 funding budget. The bill proposed a FY16 funding increase of 3% for the National Institute of Health, versus BofA/Merrill's forecast for a 1% increase. The firm said the proposed boost in funding would be a positive for the Life Sciences & Tools sector, especially iIllumina (ILMN) and Thermo Fisher (TMO) which have the most exposure.
07:25 EDTPFEPiper calls Bristol 'modestly overvalued,' starts shares with sell
Subscribe for More Information
07:14 EDTRHHBYProthena announces PRX002 was safe, well tolerated
Subscribe for More Information
05:31 EDTPFEPfizer initiated with an Overweight at Piper Jaffray
Target $45.
June 16, 2015
14:12 EDTABTAbbott backing marginally ups chances of Mylan-Perrigo deal, says BMO Capital
Subscribe for More Information
11:06 EDTABTTeva says 'fully committed' to bid for Mylan, Bloomberg reports
After Abbott (ABT) announced earlier that it intends to vote its 14.5% stake in Mylan (MYL) in favor of Mylan's proposed acquisition of Perrigo (PRGO), a Teva (TEVA) spokesperson told Bloomberg in an email that the company remains "fully committed" to is offer to acquire Mylan, which Teva said is better than Mylan's suggested deal for Perrigo.
09:21 EDTABTMylan issues statement regarding Abbott's support for Perrigo transaction
Subscribe for More Information
09:10 EDTABTAbbott confirms support for Mylan's proposed acquisition of Perrigo
Abbott (BT) confirmed its continued support for Mylan (MYL) N.V's growth strategy by stating its intent to vote its 14.5% stake in Mylan in favor of Mylan's proposed acquisition of Perrigo (PRGO). "We chose Mylan to acquire our developed markets branded generics pharmaceuticals because its scale and breadth across critical distribution channels, broad and diverse portfolio, and commitment to patients and product quality strongly positions it for success in the years to come," said Abbott. "As both Mylan's largest shareholder and its partner through our continued manufacturing relationships, Abbott has considered the entire situation and we believe Mylan's standalone strategy and acquisition of Perrigo will further enhance its platform, is strategically compelling, value enhancing for shareholders, and offers a clear path to completion. In light of these factors, we will be voting in favor of the Perrigo transaction."
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use